<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="228477">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00106938</url>
  </required_header>
  <id_info>
    <org_study_id>AVD-640-0052</org_study_id>
    <nct_id>NCT00106938</nct_id>
  </id_info>
  <brief_title>Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)</brief_title>
  <acronym>ACT I</acronym>
  <official_title>Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <brief_summary>
    <textblock>
      The study is being conducted to demonstrate the non-inferiority of carotid artery stenting
      (CAS) using the Emboshield® Embolic Protection System with the Xact® Carotid Stent System to
      carotid endarterectomy (CEA) for the treatment of asymptomatic extracranial carotid
      atherosclerotic disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomization for ACT 1 employs a 3:1 ratio of CAS versus CEA. A lead-in phase of up to 400
      carotid stent subjects will provide investigators experience with the study devices prior to
      pivotal enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision and not a result of any patient or product safety issues.
  </why_stopped>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Any Death, Stroke, and Myocardial Infarction (MI) Within 30 Days Post-index Procedure</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Major adverse events = Composite of any stroke, myocardial infarction and death during the 30-day post-procedural period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Any Death, Stroke, and MI Within 30 Days and Ipsilateral Stroke 31 Days to 365 Days</measure>
    <time_frame>0 to 365 days</time_frame>
    <description>Major adverse events = Composite of any stroke, myocardial infarction and death during the 30-day post-procedural period and ipsilateral strokes between 31 and 365 days post-procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Device Success: Xact Stent</measure>
    <time_frame>0 to 30 days post procedure</time_frame>
    <description>Acute device success is defined as attainment of final residual diameter stenosis of &lt; 50% by QCA (if QCA is not available, the visual estimate of diameter stenosis will be used) covering an area no longer than the original lesion with the study stent. (Routine post-dilatation of the stent may be included in this definition). Placement of an additional stent to treat a dissection or procedural complication as a bailout will not be considered a device success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Device Success: Embolic Protection Device System</measure>
    <time_frame>0 to 30 days post procedure</time_frame>
    <description>Acute device success is defined as attainment of final residual diameter stenosis of &lt; 50% by QCA (if QCA is not available, the visual estimate of diameter stenosis will be used) covering an area no longer than the original lesion with the study stent. (Routine post-dilatation of the stent may be included in this definition). Placement of an additional stent to treat a dissection or procedural complication as a bailout will not be considered a device success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>0 to 30 days post procedure</time_frame>
    <description>Procedural success is defined as the attainment of target lesion final residual diameter stenosis of &lt; 50% by QCA (if QCA is not available, the visual estimate of diameter stenosis will be used) using any procedural method and freedom of Major Adverse Event at 30 days.
Angiographic data was not required for CEA arm, therefore the procedure success assessment was not available for CEA arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Morbidity Measure</measure>
    <time_frame>0 to 30 Days Post-procedure</time_frame>
    <description>Composite Morbidity Measure = Cranial and peripheral nerve injury (cranial/cervical, femoral, peroneal, or other), vascular injury (including CAS access artery injury), non-cerebral bleeding, hematoma, or pseudoaneurysm, CEA wound or access artery wound, general anesthesia/allergic reaction/airway complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Clinically Indicated Target Lesion Revascularization</measure>
    <time_frame>0 to 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Clinically Indicated Target Lesion Revascularization</measure>
    <time_frame>0 to 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Clinically Indicated Target Lesion Revascularization</measure>
    <time_frame>0 to 730 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Clinically Indicated Target Lesion Revascularization</measure>
    <time_frame>0 to 1095 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Clinically Indicated Target Lesion Revascularization</measure>
    <time_frame>0 to 1460 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Clinically Indicated Target Lesion Revascularization</measure>
    <time_frame>0 to 1825 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Ipsilateral Stroke</measure>
    <time_frame>31 to 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Ipsilateral Stroke</measure>
    <time_frame>31 to 730 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Ipsilateral Stroke</measure>
    <time_frame>31 to 1095 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Ipsilateral Stroke</measure>
    <time_frame>31 to 1460 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Ipsilateral Stroke</measure>
    <time_frame>31 to 1825 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Mortality</measure>
    <time_frame>0 to 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Mortality</measure>
    <time_frame>0 to 730 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Mortality</measure>
    <time_frame>0 to 1095 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Mortality</measure>
    <time_frame>0 to 1460 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Mortality</measure>
    <time_frame>0 to 1825 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1663</enrollment>
  <condition>Carotid Artery Disease</condition>
  <condition>Carotid Stenosis</condition>
  <condition>Stroke</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Carotid artery stenting with filter (interventional)</intervention_name>
    <description>Carotid artery stenting with filter (interventional)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Carotid artery endarterectomy (surgical)</intervention_name>
    <description>Carotid artery endarterectomy (surgical)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe carotid artery disease

          -  Patients who have not had symptoms related to their carotid artery disease in the
             last 180 days

          -  Patients who are able to undergo either an interventional stenting or surgical
             procedure

        Exclusion Criteria:

          -  Patients who have had symptoms in the last 180 days

          -  Patients who are high risk for surgery

          -  Patients who have certain conditions that might confound the results of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Matsumura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Rosenfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Luke's Hospital-Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fogarty Clinical Research Inc./El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Foundation Hospital-San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cardiac and Vascular Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawaii Permanente Medical Group - Kaiser</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Hospital and Memorial Medical Center/ Prairie Heart Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkview Hospital</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Baptist Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harper University Hospital/Detroit Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLaren Regional Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Mercy Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of Lourdes Medical Center</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millard Fillmore Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester-Strong Memorial Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WakeMed Health and Hospital</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University Stroke Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heritage Valley Health System</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrisburg Hospital / Pinnacle Health</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Physicians Division of Vascular Surgery/Shadyside Medical</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Washington</city>
        <state>Pennsylvania</state>
        <zip>15301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Medical Center/Berks Cardiologists</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Hospital-SC</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Central Heart Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Stern Cardiovascular Center/Methodist Germantown Hospital</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont Holston Valley Medical Center</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical West/Turkey Creek Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westlake Medical Center/Seton Heart Institute</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Hospital of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Veteran's Administration Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Episcopal Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake General Hospital/Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital / Virginia Cardiovascular Specilists</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deaconess Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center - Milwaukee</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 13, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2005</firstreceived_date>
  <firstreceived_results_date>April 2, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carotid stenting</keyword>
  <keyword>Carotid endarterectomy</keyword>
  <keyword>Carotid artery disease with severe narrowing of the artery</keyword>
  <keyword>Stroke prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Carotid Artery Diseases</mesh_term>
    <mesh_term>Carotid Stenosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Asymptomatic subjects with extracranial internal carotid stenosis which was ≥70% &amp; ≤99% by duplex ultrasound or ≥70% &amp; ≤99% by angiography (visual estimate) with or without involvement of the contiguous common carotid artery, who could undergo carotid artery stenting/carotid endarterectomy and all follow-ups, were recruited starting from April 2005</recruitment_details>
      <pre_assignment_details>1453 patients were randomized to support the primary analysis; an additional 210 lead-in subjects were enrolled to allow investigators to gain experience with the study devices prior to randomizing subjects and were not part of the primary analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CAS Group</title>
          <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
        </group>
        <group group_id="P2">
          <title>CEA Group</title>
          <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1089"/>
                <participants group_id="P2" count="364"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="913"/>
                <participants group_id="P2" count="293"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CAS Group</title>
          <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
        </group>
        <group group_id="B2">
          <title>CEA Group</title>
          <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1089"/>
            <count group_id="B2" value="364"/>
            <count group_id="B3" value="1453"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="325"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="764"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="1025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7" spread="7.0"/>
                    <measurement group_id="B2" value="67.9" spread="6.9"/>
                    <measurement group_id="B3" value="67.7" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="423"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="666"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="985"/>
                    <measurement group_id="B2" value="327"/>
                    <measurement group_id="B3" value="1312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1089"/>
                    <measurement group_id="B2" value="364"/>
                    <measurement group_id="B3" value="1453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite of Any Death, Stroke, and Myocardial Infarction (MI) Within 30 Days Post-index Procedure</title>
        <description>Major adverse events = Composite of any stroke, myocardial infarction and death during the 30-day post-procedural period.</description>
        <time_frame>0 to 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Any Death, Stroke, and Myocardial Infarction (MI) Within 30 Days Post-index Procedure</title>
          <description>Major adverse events = Composite of any stroke, myocardial infarction and death during the 30-day post-procedural period.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Device Success: Xact Stent</title>
        <description>Acute device success is defined as attainment of final residual diameter stenosis of &lt; 50% by QCA (if QCA is not available, the visual estimate of diameter stenosis will be used) covering an area no longer than the original lesion with the study stent. (Routine post-dilatation of the stent may be included in this definition). Placement of an additional stent to treat a dissection or procedural complication as a bailout will not be considered a device success.</description>
        <time_frame>0 to 30 days post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Device Success: Xact Stent</title>
          <description>Acute device success is defined as attainment of final residual diameter stenosis of &lt; 50% by QCA (if QCA is not available, the visual estimate of diameter stenosis will be used) covering an area no longer than the original lesion with the study stent. (Routine post-dilatation of the stent may be included in this definition). Placement of an additional stent to treat a dissection or procedural complication as a bailout will not be considered a device success.</description>
          <units>percentage of devices</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1015"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>devices</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1049"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="97.4" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Device Success: Embolic Protection Device System</title>
        <description>Acute device success is defined as attainment of final residual diameter stenosis of &lt; 50% by QCA (if QCA is not available, the visual estimate of diameter stenosis will be used) covering an area no longer than the original lesion with the study stent. (Routine post-dilatation of the stent may be included in this definition). Placement of an additional stent to treat a dissection or procedural complication as a bailout will not be considered a device success.</description>
        <time_frame>0 to 30 days post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Device Success: Embolic Protection Device System</title>
          <description>Acute device success is defined as attainment of final residual diameter stenosis of &lt; 50% by QCA (if QCA is not available, the visual estimate of diameter stenosis will be used) covering an area no longer than the original lesion with the study stent. (Routine post-dilatation of the stent may be included in this definition). Placement of an additional stent to treat a dissection or procedural complication as a bailout will not be considered a device success.</description>
          <units>percentage of devices</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1022"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>devices</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1045"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="96.7" upper_limit="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>Procedural success is defined as the attainment of target lesion final residual diameter stenosis of &lt; 50% by QCA (if QCA is not available, the visual estimate of diameter stenosis will be used) using any procedural method and freedom of Major Adverse Event at 30 days.
Angiographic data was not required for CEA arm, therefore the procedure success assessment was not available for CEA arm.</description>
        <time_frame>0 to 30 days post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>Procedural success is defined as the attainment of target lesion final residual diameter stenosis of &lt; 50% by QCA (if QCA is not available, the visual estimate of diameter stenosis will be used) using any procedural method and freedom of Major Adverse Event at 30 days.
Angiographic data was not required for CEA arm, therefore the procedure success assessment was not available for CEA arm.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1025"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Morbidity Measure</title>
        <description>Composite Morbidity Measure = Cranial and peripheral nerve injury (cranial/cervical, femoral, peroneal, or other), vascular injury (including CAS access artery injury), non-cerebral bleeding, hematoma, or pseudoaneurysm, CEA wound or access artery wound, general anesthesia/allergic reaction/airway complications.</description>
        <time_frame>0 to 30 Days Post-procedure</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Morbidity Measure</title>
          <description>Composite Morbidity Measure = Cranial and peripheral nerve injury (cranial/cervical, femoral, peroneal, or other), vascular injury (including CAS access artery injury), non-cerebral bleeding, hematoma, or pseudoaneurysm, CEA wound or access artery wound, general anesthesia/allergic reaction/airway complications.</description>
          <population>ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite morbidity measure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cranial nerve injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral nerve injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-cerebral bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CEA wound or access artery wound</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
        <time_frame>0 to 180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
          <units>percentage of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8"/>
                    <measurement group_id="O2" value="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
        <time_frame>0 to 365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
          <units>percentage of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                    <measurement group_id="O2" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
        <time_frame>0 to 730 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
          <units>percentage of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7"/>
                    <measurement group_id="O2" value="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
        <time_frame>0 to 1095 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
          <units>percentage of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4"/>
                    <measurement group_id="O2" value="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
        <time_frame>0 to 1460 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
          <units>percentage of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4"/>
                    <measurement group_id="O2" value="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
        <time_frame>0 to 1825 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Clinically Indicated Target Lesion Revascularization</title>
          <units>percentage of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4"/>
                    <measurement group_id="O2" value="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Ipsilateral Stroke</title>
        <time_frame>31 to 365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Ipsilateral Stroke</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1045"/>
                <count group_id="O2" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                    <measurement group_id="O2" value="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Ipsilateral Stroke</title>
        <time_frame>31 to 730 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Ipsilateral Stroke</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1045"/>
                <count group_id="O2" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0"/>
                    <measurement group_id="O2" value="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Ipsilateral Stroke</title>
        <time_frame>31 to 1095 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Ipsilateral Stroke</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1045"/>
                <count group_id="O2" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4"/>
                    <measurement group_id="O2" value="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Composite of Any Death, Stroke, and MI Within 30 Days and Ipsilateral Stroke 31 Days to 365 Days</title>
        <description>Major adverse events = Composite of any stroke, myocardial infarction and death during the 30-day post-procedural period and ipsilateral strokes between 31 and 365 days post-procedure.</description>
        <time_frame>0 to 365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Any Death, Stroke, and MI Within 30 Days and Ipsilateral Stroke 31 Days to 365 Days</title>
          <description>Major adverse events = Composite of any stroke, myocardial infarction and death during the 30-day post-procedural period and ipsilateral strokes between 31 and 365 days post-procedure.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Ipsilateral Stroke</title>
        <time_frame>31 to 1460 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Ipsilateral Stroke</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1045"/>
                <count group_id="O2" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8"/>
                    <measurement group_id="O2" value="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Ipsilateral Stroke</title>
        <time_frame>31 to 1825 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Ipsilateral Stroke</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1045"/>
                <count group_id="O2" value="333"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8"/>
                    <measurement group_id="O2" value="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Mortality</title>
        <time_frame>0 to 365 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Mortality</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5"/>
                    <measurement group_id="O2" value="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Mortality</title>
        <time_frame>0 to 730 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Mortality</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2"/>
                    <measurement group_id="O2" value="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Mortality</title>
        <time_frame>0 to 1095 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Mortality</title>
          <units>percentage of partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                    <measurement group_id="O2" value="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Mortality</title>
        <time_frame>0 to 1460 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Mortality</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5"/>
                    <measurement group_id="O2" value="93.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Mortality</title>
        <time_frame>0 to 1825 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CAS Group</title>
            <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
          <group group_id="O2">
            <title>CEA Group</title>
            <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Mortality</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1089"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1"/>
                    <measurement group_id="O2" value="89.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through 1 year post procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CAS Group</title>
          <description>CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
        </group>
        <group group_id="E2">
          <title>CEA Group</title>
          <description>CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="376" subjects_at_risk="1089"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>GI bleed</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="814"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="814"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal lab test</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="814"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="814"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="814"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="70" subjects_affected="57" subjects_at_risk="814"/>
                <counts group_id="E2" events="25" subjects_affected="21" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Structural heart disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="814"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="39" subjects_affected="29" subjects_at_risk="814"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="28" subjects_affected="25" subjects_at_risk="814"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Miscellaneous</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="814"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="814"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="814"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="814"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="814"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="814"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Vessel trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="814"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="45" subjects_affected="41" subjects_at_risk="814"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="814"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Cranial nerve palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Hyperperfusion syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Neurologic other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="814"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Peripheral neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="814"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>TIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="814"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Ipsilateral major</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="814"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Ipsilateral minor</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="814"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Non-ipsilateral major</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Non-ipsilateral minor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental health related</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="814"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="814"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Anesthesia/Procedural medication related</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="814"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Cranial nerve injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="814"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Heparin induced thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="814"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="69" subjects_affected="69" subjects_at_risk="814"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Vessel trauma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="814"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="814"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="814"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Abdominal Aortic Aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="814"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Contralateral stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="814"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="56" subjects_affected="41" subjects_at_risk="814"/>
                <counts group_id="E2" events="20" subjects_affected="11" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Renal artery disease</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="814"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="814"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Target lesion restenosis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="814"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="635" subjects_at_risk="1089"/>
                <counts group_id="E2" subjects_affected="216" subjects_at_risk="364"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="115" subjects_affected="93" subjects_at_risk="814"/>
                <counts group_id="E2" events="41" subjects_affected="33" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="140" subjects_affected="107" subjects_at_risk="814"/>
                <counts group_id="E2" events="47" subjects_affected="40" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="92" subjects_affected="81" subjects_at_risk="814"/>
                <counts group_id="E2" events="31" subjects_affected="23" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anesthesia/Procedural medication related</sub_title>
                <counts group_id="E1" events="70" subjects_affected="65" subjects_at_risk="814"/>
                <counts group_id="E2" events="55" subjects_affected="51" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="148" subjects_affected="140" subjects_at_risk="814"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Cranial nerve injury</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="814"/>
                <counts group_id="E2" events="51" subjects_affected="48" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="74" subjects_affected="73" subjects_at_risk="814"/>
                <counts group_id="E2" events="31" subjects_affected="30" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="814"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="268" subjects_affected="252" subjects_at_risk="814"/>
                <counts group_id="E2" events="36" subjects_affected="35" subjects_at_risk="282"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="60" subjects_affected="56" subjects_at_risk="814"/>
                <counts group_id="E2" events="66" subjects_affected="64" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="58" subjects_affected="51" subjects_at_risk="814"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="211" subjects_affected="173" subjects_at_risk="814"/>
                <counts group_id="E2" events="36" subjects_affected="28" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="66" subjects_affected="56" subjects_at_risk="814"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="51" subjects_affected="50" subjects_at_risk="814"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="282"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer M Jones-McMeans, PhD (Associate Director Clinical Research)</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>408-845-1459</phone>
      <email>jennifer.jones@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
